RecruitingPhase 3NCT06679270
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Studying OBSOLETE: Laminopathy type Decaudain-Vigouroux
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amryt Pharma
- Intervention
- Metreleptin(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 13 years · All sexes
- Timeline
- 2024 – 2028
Study locations (7)
- University of Alabama, Birmingham, Alabama, United States
- Flourish Research, Boca Raton, Florida, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Michigan, Ann Arbour, Michigan, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06679270 on ClinicalTrials.gov